PeproMene Bio, Inc. anuncia avances en su ensayo clínico sobre linfoma no Hodgkin de células B de PMB-CT01

Posted on by

– PeproMene Bio, Inc. anuncia la finalización de la cohorte de primera dosis y la apertura de la cohorte de segunda dosis en su ensayo clínico de fase 1 sobre linfoma no Hodgkin de células B (B-NHL) de PMB-CT01 (células T BAFFR-CAR) IRVINE, California, 11 de septiembre de 2023…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.